Peregrine Pharmaceuticals Provides Update On Status Of Cotara Phase III

Peregrine Pharmaceuticals Reports Voting Results of Annual Meeting

Peregrine Pharmaceuticals Provides Update on Status of Cotara Phase III

Peregrine Pharmaceuticals Announces Grant of Patent for New Vascular Targeting Agents

Peregrine Pharmaceuticals Presents Vascular Targeting Agent Platform At the 2002 Antibody World Summit; Company Announces Quarterly Conference Call

Peregrine Pharmaceuticals Receives Notice From Nasdaq to Start 180-Day Grace Period to Regain Compliance with Nasdaq Listing Requirements

Peregrine Pharmaceuticals Announces $1,856,000 Investment from Institutional Investor; Over $10 Million in Cash and Cash Commitments on Hand; Conference Call Set for 11:00 AM EDT, Aug. 15

Peregrine Pharmaceuticals Announces $7.1 Million Private Investment Commitment From Institutional Investors

Peregrine Pharmaceuticals Submits Extension to File Its Annual Report On Form 10-K; Quarterly Conference Call To Be Rescheduled

Peregrine Pharmaceuticals' Quarterly Conference Call Rescheduled for Tuesday, July 30